Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients

Renal Failure

Volumn 29, Issue 7, 2007, Pages 849-854

  Saglam, Funda ^a   Cavdar, Caner ^a   Uysal, Sezer ^a   Cavdar, Zahide ^a   Camsari, Taner ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Iron; Oxidative stress; Peritoneal dialysis

Indexed keywords

C REACTIVE PROTEIN; CATALASE; FERRIC HYDROXIDE SUCROSE; FERRITIN; GLUTATHIONE PEROXIDASE; HEMOGLOBIN; IRON; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; MAINTENANCE THERAPY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; AGED; C-REACTIVE PROTEIN; FEMALE; FERRIC COMPOUNDS; GLUTATHIONE PEROXIDASE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; SUCROSE;

EID: 36348956161     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701573566     Document Type: Article

References (30)

1. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stres in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272-1280.
2. Galle J. Oxidative stres in chronic renal failure. Nephrol Dial Transplant. 2001;16:2135-2137.
3. Epperlein MM, Nourooz-Zadeh J, Jayasena SD, et al. Nature and biological significance of free radicals generated during bicarbonate hemodialysis. J Am Soc Nephrol. 1998;9:457-463.
4. Camsari T, Cavdar C, Ozture H, Onvural B, Semin I, Celik A, et al. Effects of conventional heparin and low-molecular-weight heparin treatment on lipid metabolism during a single hemodialysis session. Nephron. 1999;82(3):286-288.
5. Rousselot DB, Jaudon MC, Issad B, Cacoub P, Congy F, Jardel C. Antioxidant status of elderly chronic renal patients treated by continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1997;12:1399-1405.
6. Özden M, Maral H, Akaydýn D, Çetinalp P, Kalender B. Erythrocyte glutathione peroxidase activity, plasma malondialdehyde and erythrocyte glutathione levels in hemodialysis and CAPD patients. Clin Biochem. 2002;35(4):269-273.
7. Ross EA, Koo LC, Moberly JB. Low whole blood erythrocyte levels of glutathione in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1997;30(4):489-494.
8. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13:504-510.
9. Agarwal R, Vasavada N, Sachs N, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004;65:2279-2289.
10. Lim S, Wei Y, Leng Yu, Kho B. Enhanced oxidative stress in hemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant. 1999;14:2680-2687.
11. Roob M, Khoschsorur G, Tiran A, Horina J, Holzer H, Winklhofer-Roob M. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol. 2000;11:539-549.
12. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis. 2001 Jan;37(1 Suppl. 1):S182-S238.
13. Yi Sun, Oberley L, Ying Li. A simple method for clinical assay of SOD. Clin Chem. 1988;3413:497-500.
14. Stocks J, Dormandy TL. Autooxidation of human red cell lipids induced by hydrogen peroxide. Br J Hematology. 1971;20:95-111.
15. Macdougall I. Intravenous administration of iron in epoetin treated hemodialysis patients - which drugs, which regimen? Nephrol Dial Transplant. 2000;15:1743-1745.
16. Clermont G, Lecour S, Lahet JJ, Siohan P, Vergely C, Chevet D, et al. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: A possible explanation for the increased cardiovascular risk in these patients. Cardiovascular Research. 2000;47:618-623.
17. Gali F, Rovidati S, Benedetti S, Buoncristiani U, Covarelli C, Floridi A, et al. Overexpression of erythrocyte glutathione S-transferase in uremia and dialysis. Clin Chem. 1999;45/10:1781-1788.
18. Bolton C, Downs LG, Victory JG, Dwight JV, Tomson C, Mackness MI, et al. Endothelial dysfunction in chronic renal failure. Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001;16:1189-1197.
19. Lim PS, Chang YM, Thien YM, Wang NP, Yang CC, Chen TT, et al. 8-Isoprostaglandin F2- as a useful clinical biomarkers of oxidative stress in ESRD patients. Blood Purif. 2002;20:537-542.
20. Rudko I, Balashova T, Ermolenko V. The role of lipid peroxidation and Na+- H+ exchange in the membranoprotective action of erythropoietin. Bio- News Scientific NR. 1993;28:5-41.
21. Cavdar C, Camsari T, Semin I, Gönenç S, Açý kgöz O. Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol. 1997;31:371-375.
22. Klahr S, Amico GD. Second International Symposium on Lipids, Atherosclerosis, and the Kidney: Summary of scientific presentations. Nephrol Dial Transplant. 1994;9:1660-1663.
23. Lim S, Vaziri N. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int. 2004;65:1802-1809.
24. Fishbane S, John K, Muesaka K, Mittal S. Is there material hazard to treatment with intravenous iron? Nephrol Dial Transplant. 1999;14:2595-2598.
25. Cavdar C, Temiz A, Yenicerioglu Y, Caliskan S, Celik A, Sifil A, et al. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol. 2003;37:77-82.
26. Cighetti G, Duca L, Bortone L, Sala S, Nava I, et al. Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest. 2002;23(1):55-60.
27. Gaenzer H, Marschang P, Sturm W, Neumayr G, Vogel W, Patsch J, Weiss G.Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol. 2002;18;40(12):2189-2194.
28. Reddi A, Bollineni J, Baskin S, Nimmagadda V, Baker H. Serum ferritin and oxidative stress in patients undergoing hemodialysis. Nephron. 2000;86:202-203.
29. Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of ironhydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arneimittelforschung. 1996;46(6):615-621.
30. Jensen HS. C reactive protein. Ugeskr Laeger. 2000;162(17):2453- 2456.